靶点- |
|
在研机构- |
|
在研适应症- |
|
最高研发阶段无进展 |
首次获批国家/地区- |
首次获批日期- |
A Phase I Study to Determine Safety, Tolerability and Bioactivity of Nexvax2 in HLA DQ2+ Volunteers With Coeliac Disease Following a Long-term, Strict Gluten-free Diet
The main purpose of this study is to determine the safety of weekly injections of Nexvax2 given for three weeks to patients with coeliac disease who have been on a gluten-free diet.
The second purpose of this study is to compare the immune response over the three week study period in coeliac disease patients given Nexvax2 compared to those given saline.
100 项与 Nexpep Pty Ltd. 相关的临床结果
0 项与 Nexpep Pty Ltd. 相关的专利(医药)
100 项与 Nexpep Pty Ltd. 相关的药物交易
100 项与 Nexpep Pty Ltd. 相关的转化医学